<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00424905</url>
  </required_header>
  <id_info>
    <org_study_id>PM_L_0199</org_study_id>
    <secondary_id>EudraCT # : 2006-002482-39</secondary_id>
    <nct_id>NCT00424905</nct_id>
  </id_info>
  <brief_title>DIAMANTE - Diseases Infectious Analysis Microflora Antibiotic Effect</brief_title>
  <official_title>Evaluation of the Effects of Enterogermina, 2 Billion Bacillus Clausii Spores, on the Intestinal Flora of Children Antibiotic Treated for Bacterial Upper Respiratory Tract Infections: Open, Pilot Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      To assess the effects of Bacillus clausii (Enterogermina®) on fecal microbial flora (using&#xD;
      Polymerase Chain Reaction - Denaturing Gradient Gel Electrophoresis - PCR-DGGE - Method) in&#xD;
      antibiotic-treated children with complicated acute otitis media or beta-hemolytic&#xD;
      streptococcal pharyngo-tonsillitis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes of microbial composition of fecal bacterial flora by PCR-DGGE analysis.</measure>
    <time_frame>between samples obtained at baseline and follow-up</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline of body weight</measure>
    <time_frame>During the total study period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of abdominal symptoms</measure>
    <time_frame>Daily</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of Bacillus clausii spores in feces</measure>
    <time_frame>after heat shock treatment on selective medium.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and rate of patients with GI symptoms and time to first development of symptoms.</measure>
    <time_frame>recorded in a daily diary card for the total study period</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Gastrointestinal Diseases</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Enterogermina® vials containing 2×109 spores of polyantibiotic resistant Bacillus clausii (test drug)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No treatment (reference group)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bacillus clausii</intervention_name>
    <description>2 Enterogermina vials/day for 12 to 17 days (i.e. during the 5 to 10-days antibiotic treatment and for 7 days thereafter.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects with persistency of symptoms and requiring antibiotics for bacterial upper&#xD;
             respiratory tract infections, i.e. complicated acute otitis media (diagnosed by&#xD;
             otoscopic examination) or beta-haemolytic streptococcal pharyngo-tonsillitis&#xD;
             (diagnosed by pharyngeal swab and rapid antigen detection test or positive culture);&#xD;
&#xD;
          -  Outpatients or patients attending an emergency room for both diagnoses, and inpatients&#xD;
             in case of complicated acute otitis media;&#xD;
&#xD;
          -  Written informed consent from both parents.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of clinically significant chronic diseases, or chronic diseases necessitating&#xD;
             the use of continuous drug therapies, or of any disease that may interfere with the&#xD;
             successful completion or the objectives of the trial;&#xD;
&#xD;
          -  Clinical evidence of relevant cardiovascular, respiratory, renal, hepatic,&#xD;
             gastrointestinal, hematological, neurological or of any disease that may interfere&#xD;
             with the successful completion or the objectives of the trial;&#xD;
&#xD;
          -  Use of antibiotics, prebiotics or probiotics (medications or dietetic supplements) in&#xD;
             the last 2 weeks prior to study entry;&#xD;
&#xD;
          -  Hypersensitivity to the investigational product;&#xD;
&#xD;
          -  Subjects enrolled in another trial in the previous three months.&#xD;
&#xD;
        The above information is not intended to contain all considerations relevant to a patient's&#xD;
        potential participation in a clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>5 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Georges Paizis, MD</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>November 2008</verification_date>
  <study_first_submitted>January 19, 2007</study_first_submitted>
  <study_first_submitted_qc>January 19, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 22, 2007</study_first_posted>
  <last_update_submitted>November 28, 2008</last_update_submitted>
  <last_update_submitted_qc>November 28, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 1, 2008</last_update_posted>
  <responsible_party>
    <name_title>Medical Affairs Medical Director</name_title>
    <organization>Sanofi-aventis administrative office</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastrointestinal Diseases</mesh_term>
    <mesh_term>Digestive System Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

